Literature DB >> 1524280

Selective polysaccharide antibody deficiency in familial DiGeorge syndrome.

M S Schubert1, R B Moss.   

Abstract

A family including three children with DiGeorge syndrome is described. One child died in the neonatal period from cardiac anomalies accompanying complete DiGeorge syndrome. The two surviving siblings shared a common set of pharyngeal pouch anomalies and immunodeficiency consistent with partial DiGeorge syndrome, and other morphologic anomalies characteristic of the velocardiofacial syndrome with which familial DiGeorge syndrome is associated (reviewed in reference 1). Both had normal karyotypes. Both presented with recurrent otitis media and sinopulmonary infections, CD4+ T cell lymphopenia, and defective DCH skin test responses to recall T cell antigens. Both had low serum IgM levels and IgG4 levels at the lower limits of normal. Immunization with bacterial polysaccharides resulted in impaired IgG antibody responses to the same set of antigens (H. influenzae polyribophosphate and S. pneumoniae capsular serotypes 9N and 14), while responses to protein antigens were intact. Both siblings were treated successfully with intravenous gamma globulin. The pattern of selective antibody deficiency in these patients with familial DiGeorge syndrome suggests a heritable lesion in certain regulatory antipolysaccharide CD4+ T cell subpopulations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1524280

Source DB:  PubMed          Journal:  Ann Allergy        ISSN: 0003-4738


  11 in total

Review 1.  New frontiers in primary immunodeficiency disorders: immunology and beyond….

Authors:  Eleonora Gambineri
Journal:  Cell Mol Life Sci       Date:  2011-10-19       Impact factor: 9.261

2.  Secondary immunologic consequences in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  R Zemble; E Luning Prak; K McDonald; D McDonald-McGinn; E Zackai; K Sullivan
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

Review 3.  Immunological aspects of 22q11.2 deletion syndrome.

Authors:  A R Gennery
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

4.  Longitudinal analysis of lymphocyte function and numbers in the first year of life in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).

Authors:  K E Sullivan; D McDonald-McGinn; D A Driscoll; B S Emanuel; E H Zackai; A F Jawad
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

5.  Atopic eczema is associated with delayed maturation of the antibody response to pneumococcal vaccine.

Authors:  P D Arkwright; L Patel; A Moran; M R Haeney; C I Ewing; T J David
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

6.  Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome.

Authors:  A R Gennery; D Barge; J J O'Sullivan; T J Flood; M Abinun; A J Cant
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791

7.  22q11.2 Deletion Syndrome due to a Translocation t(6;22) in a Patient Conceived via in vitro Fertilization.

Authors:  Anelisa Gollo Dantas; Adriana Bortolai; Mariana Moysés-Oliveira; Sylvia Takeno Herrero; Adriana Azoubel Antunes; Beatriz Tavares Costa-Carvalho; Vera Ayres Meloni; Maria Isabel Melaragno
Journal:  Mol Syndromol       Date:  2015-11-14

Review 8.  Primary selective IgM deficiency: an ignored immunodeficiency.

Authors:  Ankmalika Gupta Louis; Sudhir Gupta
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

9.  Post-natal ontogenesis of the T-cell receptor CD4 and CD8 Vbeta repertoire and immune function in children with DiGeorge syndrome.

Authors:  Caterina Cancrini; Maria Luisa Romiti; Andrea Finocchi; Silvia Di Cesare; Patrizia Ciaffi; Claudia Capponi; Savita Pahwa; Paolo Rossi
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.542

Review 10.  Immunodeficiency in DiGeorge Syndrome and Options for Treating Cases with Complete Athymia.

Authors:  E Graham Davies
Journal:  Front Immunol       Date:  2013-10-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.